EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA (AMIPREP)
Primary Purpose
Osteoarthritis
Status
Completed
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
injection of microfat and plasma rich platelet PRP
MRI
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Males and females between 20 and 75 years of age
- Symptomatic radio-carpal osteoarthritis diagnosed by arthroscanner resistant to medical treatment and candidate to surgery
- BMI ≥ 20 Kg/m²
- Written informed consent, signed by patient or legal representative (if patient unable to sign).
- HB > 10g/dl
- Negative pregnancy test and efficiency contraception
Exclusion Criteria:
- - Thrombocytopenia < 150 G/L, Thrombocytosis > 450 G/L, Thrombopathy
- TP < 70%, TCA patient / witness rapport > 1,20
- Anemia: HB < 10g/dl
- Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA
- Treatment by platelet inhibiting agent, aspirin, antivitamin K completed more than 2 weeks before inclusion
- Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks before inclusion
- Intra articular injection of corticosteroid or hyaluronic acid completed more than 8 weeks before inclusion
- NSAI treatment completed more than 2 weeks before inclusion
- Fever or recent disease completed more than 1 month before inclusion
- Auto immune disease, Inflammatory or microcrystalline Arthritis, Immune deficit
- Infectious disease
- MRI contraindication: ocular loose bodies, pace maker, neurostimulator, cochlear implant, vascular clips, metallic cardiac val
- Anesthesia or surgery contra indication, iodine allergy
Sites / Locations
- Assisatnce Publique Hopitaux de Marseille
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intra-articular injection
Arm Description
Outcomes
Primary Outcome Measures
evaluate the safety
By the number of Adverse event related to the traitment
Secondary Outcome Measures
Improvement of pain
with the Visual Analogue Scale (VAS).
Improvement of wrist pain
with DASH scores
Improvement of wrist pain and function
with PWRE scores
Improvement of radiocarpal chondral lesions
MRI
Full Information
NCT ID
NCT03164122
First Posted
May 19, 2017
Last Updated
August 12, 2022
Sponsor
Assistance Publique Hopitaux De Marseille
1. Study Identification
Unique Protocol Identification Number
NCT03164122
Brief Title
EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA
Acronym
AMIPREP
Official Title
EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
May 22, 2017 (Actual)
Primary Completion Date
June 7, 2018 (Actual)
Study Completion Date
June 7, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Recently, the emergence of biotherapies has allowed the use of intra-articular injections of autologous plasma rich platelet (PRP). Their use is widespread since 2010 and is based on the demonstration that platelets-enriched plasma, by virtue of its growth factors concentration, stimulates in vitro and in vivo cartilage regeneration in preclinical models. Recent literature highlights that these autologous products are very well tolerated by humans. PRP, as an intra-articular injection therapy, seems to be an autologous biological medicine, innovative for cartilage injury reparation and showing good primary results for this indication.
Adipose tissue contains stromal-vascular fraction (SVF), in which are located a large proportion of mesenchymal multipotent stem cells (Adipose-derived stem cells, ADSCs) able to differentiate into several cellular lines in vitro and in vivo, including cartilage cells.
The association of microfat and PRP is interesting in order to potentiate trophic and regenerative effects on damaged cartilage site. The combination of these two products, respectively rich in autologous multipotent stem cells and growth factors, aims to create an optimal environment for cartilage cells regeneration. Furthermore, microfat semi solid phase is playing the role of a nutritive support matrix which contains and limits the diffusion and resorption of PRP liquid while allowing progressive growth factors release on the injection site.
The hypothesis of this project is that standardized injection of an innovative treatment (microfat and autologous PRP) should allow delay the use of invasive surgical therapy in the treatment of wrist osteoarthritis. This minimally invasive treatment could provide a curative second line treatment in case of medical treatment failure.
Detailed Description
Material and methods:
This research protocol aims to evaluate the safety of intra-articular injection of a mixture of autologous microfat associated with autologous PRP for radiocarpal osteoarthritis resistant to medical treatment.
This is a prospective, longitudinal, intrasubject, single-center clinical trial phase I-IIa evaluating the safety and feasibility of this innovative treatment.
Twelve patients will receive an intra-articular injection of 4 ml of an homogeneous mixture of autologous PRP (2ml) and microfat (2ml).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intra-articular injection
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
injection of microfat and plasma rich platelet PRP
Intervention Description
intra-articular injections
Intervention Type
Device
Intervention Name(s)
MRI
Intervention Description
MRI 3T
Primary Outcome Measure Information:
Title
evaluate the safety
Description
By the number of Adverse event related to the traitment
Time Frame
1 MONTH
Secondary Outcome Measure Information:
Title
Improvement of pain
Description
with the Visual Analogue Scale (VAS).
Time Frame
3 ,6, 12 months
Title
Improvement of wrist pain
Description
with DASH scores
Time Frame
3 ,6, 12 months
Title
Improvement of wrist pain and function
Description
with PWRE scores
Time Frame
3, 6,12 months
Title
Improvement of radiocarpal chondral lesions
Description
MRI
Time Frame
12 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males and females between 20 and 75 years of age
Symptomatic radio-carpal osteoarthritis diagnosed by arthroscanner resistant to medical treatment and candidate to surgery
BMI ≥ 20 Kg/m²
Written informed consent, signed by patient or legal representative (if patient unable to sign).
HB > 10g/dl
Negative pregnancy test and efficiency contraception
Exclusion Criteria:
- Thrombocytopenia < 150 G/L, Thrombocytosis > 450 G/L, Thrombopathy
TP < 70%, TCA patient / witness rapport > 1,20
Anemia: HB < 10g/dl
Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA
Treatment by platelet inhibiting agent, aspirin, antivitamin K completed more than 2 weeks before inclusion
Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks before inclusion
Intra articular injection of corticosteroid or hyaluronic acid completed more than 8 weeks before inclusion
NSAI treatment completed more than 2 weeks before inclusion
Fever or recent disease completed more than 1 month before inclusion
Auto immune disease, Inflammatory or microcrystalline Arthritis, Immune deficit
Infectious disease
MRI contraindication: ocular loose bodies, pace maker, neurostimulator, cochlear implant, vascular clips, metallic cardiac val
Anesthesia or surgery contra indication, iodine allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
jean-olivier ARNAUD
Organizational Affiliation
Assistance Publique Hopitaux De Marseille
Official's Role
Study Director
Facility Information:
Facility Name
Assisatnce Publique Hopitaux de Marseille
City
Marseille
ZIP/Postal Code
13354
Country
France
12. IPD Sharing Statement
Learn more about this trial
EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA
We'll reach out to this number within 24 hrs